| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $88M | ||
| $62M |
Buys | $926,801 | 3 | 50 |
Sells | $6,267 | 3 | 50 |
| SCHIMMEL PAUL | director | 2 | $911,801 | 0 | $0 | $911,801 |
| Gross Jane A | director | 1 | $15,000 | 0 | $0 | $15,000 |
| DENYES NANCY | General Counsel | 0 | $0 | 1 | $1,091 | $-1,091 |
| Broadfoot Jill Marie | Chief Financial Officer | 0 | $0 | 1 | $1,521 | $-1,521 |
| Shukla Sanjay | President and CEO | 0 | $0 | 1 | $3,655 | $-3,655 |
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Over the last 12 months, insiders at aTyr Pharma, Inc. have bought $926,801 and sold $6,267 worth of aTyr Pharma, Inc. stock.
On average, over the past 5 years, insiders at aTyr Pharma, Inc. have bought $560,345 and sold $7,203 worth of stock each year.
Highest buying activity among insiders over the last 12 months: SCHIMMEL PAUL (director) — $911,801. Gross Jane A (director) — $15,000.
The last purchase of 317,999 shares for transaction amount of $299,364 was made by SCHIMMEL PAUL (director) on 2025‑10‑09.
| 2026-02-04 | Sale | Shukla Sanjay | President and CEO | 3,745 0.0042% | $0.98 | $3,655 | +5.26% | |
| 2026-02-04 | Sale | Broadfoot Jill Marie | Chief Financial Officer | 1,558 0.0018% | $0.98 | $1,521 | +5.26% | |
| 2026-02-04 | Sale | DENYES NANCY | General Counsel | 1,118 0.0013% | $0.98 | $1,091 | +5.26% | |
| 2025-10-09 | SCHIMMEL PAUL | director | 317,999 0.4141% | $0.94 | $299,364 | -14.61% | ||
| 2025-10-08 | SCHIMMEL PAUL | director | 682,001 0.8473% | $0.90 | $612,437 | -18.51% | ||
| 2025-03-17 | Gross Jane A | director | 3,750 0.0208% | $4.00 | $15,000 | -73.32% | ||
| 2025-02-04 | Sale | Broadfoot Jill Marie | Chief Financial Officer | 1,254 0.0066% | $3.78 | $4,740 | -14.44% | |
| 2025-02-04 | Sale | DENYES NANCY | General Counsel | 899 0.0047% | $3.78 | $3,398 | -14.44% | |
| 2024-07-24 | SCHIMMEL PAUL | director | 52,300 0.1398% | $1.93 | $101,038 | +71.24% | ||
| 2024-07-23 | SCHIMMEL PAUL | director | 6,648 0.0167% | $1.82 | $12,075 | +76.20% | ||
| 2024-07-22 | SCHIMMEL PAUL | director | 41,052 0.0989% | $1.74 | $71,500 | +76.88% | ||
| 2024-06-05 | DENYES NANCY | General Counsel | 5,000 0.0128% | $1.86 | $9,276 | +70.33% | ||
| 2017-11-13 | Sale | EcoR1 Capital Fund Qualified, L.P. | 10 percent owner | 1,083 0.0059% | $3.95 | $4,278 | ||
| 2017-11-10 | Sale | EcoR1 Capital Fund Qualified, L.P. | 10 percent owner | 5,860 0.0324% | $4.00 | $23,445 | ||
| 2017-11-09 | Sale | EcoR1 Capital Fund Qualified, L.P. | 10 percent owner | 5,819 0.0334% | $4.15 | $24,151 | ||
| 2017-11-08 | Sale | EcoR1 Capital Fund Qualified, L.P. | 10 percent owner | 1,070 0.0064% | $4.30 | $4,601 | ||
| 2017-11-01 | EcoR1 Capital Fund Qualified, L.P. | 10 percent owner | 24,728 0.1642% | $4.80 | $118,694 | |||
| 2017-10-01 | EcoR1 Capital Fund Qualified, L.P. | 10 percent owner | 4,879 0.0341% | $5.05 | $24,639 |
| SCHIMMEL PAUL | director | 1413023 1.4421% | $1.26M | 5 | 0 | +74.78% |
| Shukla Sanjay | President and CEO | 153553 0.1567% | $137,353.16 | 0 | 1 | |
| Broadfoot Jill Marie | Chief Financial Officer | 37296 0.0381% | $33,361.27 | 0 | 2 | |
| DENYES NANCY | General Counsel | 33124 0.0338% | $29,629.42 | 1 | 2 | +70.33% |
| Gross Jane A | director | 9750 0.01% | $8,721.38 | 1 | 0 | |
| EcoR1 Capital Fund Qualified, L.P. | 10 percent owner | 3209316 3.2753% | $2.87M | 2 | 4 |
$5,413,611 | 159 | 6.12% | $94.8M | |
$155,630,608 | 79 | -24.53% | $96.35M | |
$17,525,882 | 60 | 5.22% | $95.91M | |
$4,898,715 | 46 | 40.75% | $87.35M | |
$77,146,704 | 43 | 13.28% | $99.79M | |
$909,129 | 37 | 42.19% | $86.79M | |
$33,128,160 | 18 | -13.64% | $74.37M | |
$20,234,041 | 17 | 2.09% | $72.99M | |
$3,763,566 | 15 | -21.70% | $80.82M | |
$11,267,080 | 15 | -22.36% | $79.47M | |
$17,741,707 | 13 | 30.23% | $103.98M | |
$1,073,250 | 10 | 19.46% | $98.93M | |
$280,338 | 8 | 34.18% | $96.92M | |
$68,692,148 | 6 | -39.10% | $100.99M | |
$106,599,960 | 6 | -7.63% | $83.01M | |
$110,013 | 5 | 6.58% | $74.77M | |
aTyr Pharma, Inc. (ATYR) | $193,889 | 4 | 73.66% | $87.65M |
$112,382,168 | 4 | -48.89% | $94.31M | |
$19,175,155 | 2 | 40.00% | $78.34M |
| Increased Positions | 39 | +27.66% | 6M | +9.75% |
| Decreased Positions | 61 | -43.26% | 14M | -22.66% |
| New Positions | 16 | New | 2M | New |
| Sold Out Positions | 36 | Sold Out | 7M | Sold Out |
| Total Postitions | 119 | -15.6% | 54M | -12.92% |